98%
921
2 minutes
20
Background: Myasthenia gravis (MG) is an autoimmune disorder affecting the neuromuscular junction (NMJ), driven by T cells, mediated by B cells, and dependent on autoantibodies. In addition to the typical motor symptoms of fluctuating weakness, the non-motor symptoms are also prevalent among MG patients. This review aims to present the non-motor symptoms of MG and their potential pathogenesis, hoping to contribute to personalized diagnosis and treatment.
Methods: This review elaborates the non-motor symptoms of MG and systematically detail, for the first time, their potential pathogenic mechanisms, offering a new perspective for clinical evaluation.
Results: The non-motor symptoms of MG include autonomic disorders (urinary, gastrointestinal, cardiovascular and ocular dysfunction), sensory disability (olfactory abnormalities, gustatory reduction and headaches), cognitive impairment, sleep disturbances, psychological problems (depression and anxiety), and TAMG-associated specific syndromes. Due to their insidious onset and lack of awareness, these symptoms are often overlooked. We review the non-motor symptoms of MG and first provide a systematic and detailed discussion on their potential mechanisms, including the influence of MG-specific antibodies (cross-reactivity of AChR-Ab, expression of MuSK-Ab, and striational antibodies at related functional sites), dysregulation of inflammatory factors and immune cells, collateral effects of motor symptoms, impacts of MG comorbidities, and paraneoplastic syndromes caused by thymoma.
Conclusion: Non-motor symptoms are common in MG patients. Given a series of potential mechanisms probably involved exploring these non-motor symptoms will not only enhance our understanding of MG but also aid in diagnosis and the development of precise, personalized treatments, ultimately improving the overall life quality of patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304524 | PMC |
http://dx.doi.org/10.1111/ene.70309 | DOI Listing |
Neurol Neurochir Pol
September 2025
Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
Eur J Neurol
September 2025
Department of Neuroscience 'Rita Levi Montalcini', University of Torino, Torino, Italy.
Background: The factors contributing to a poor response to subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson's disease (PD) are not yet fully understood. Accordingly, predicting the outcome might be challenging particularly in those who display an optimal response to the Levodopa challenge test.
Objective: To determine which factors may contribute to poor outcome of STN-DBS in PD.
Rev Neurol
August 2025
Tecnologico de Monterrey, School of Medicine and Health Sciences, 64710 Monterrey, Nuevo León, Mexico.
Introduction: While there is a growing body of evidence indicating a potential connection between Parkinson's disease and diabetes mellitus, there is a lack of focus on investigating how diabetes correlates with the severity of both motor and non-motor symptoms in Parkinson's disease.
Objective: This study examined and contrasted both motor and non-motor symptoms in patients diagnosed with Parkinson's disease, stratified by the presence or absence of diabetes.
Methods: A total of 40 Parkinson's disease patients, divided into two groups (with and without diabetes), were assessed using various scales, including the Movement Disorders Society - Unified Parkinson's Disease Rating Scale, Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction and Non-Motor Symptoms, Beck Depression Inventory, Montreal Cognitive Assessment, and Parkinson's Disease Questionnaire-39.
Parkinsonism Relat Disord
September 2025
Federal University of São Paulo, Department of Neurology and Neurosurgery, São Paulo, SP, Brazil.
Background: Huntington disease-like 2 (HDL2) is an autosomal dominant disorder caused by an abnormal CAG/CTG repeat in exon 2A of junctophilin-3. This is the most common Huntington's Disease phenocopy and is characterized by psychiatric, cognitive, and movement disorders. This study aimed to describe the clinical phenotype of HDL2 patients in Brazil and compare the findings with those in the literature.
View Article and Find Full Text PDFJ Neurol Neurosurg Psychiatry
September 2025
Department of Management, University of Verona, Verona, Italy.
Background: Functional motor disorders (FMD) cause long-term disability and economic burden. There is a need for multidisciplinary interventions to manage both motor and non-motor symptoms. We aim to evaluate the clinical and economic effects of integrating digital telemedicine into multidisciplinary FMD management.
View Article and Find Full Text PDF